- Pharmaceutical Executive-11-01-2022
- Volume 42
- Issue 11
Recaps, Live & In Person
Executives share insights at recent conferences.
Held for the first time in person the second week of October, Reuters Pharma 2022 in Nice, France brought a lot of energy and excitement back to this staple European event, previously produced by eyeforpharma and held annually in Barcelona. The
What makes this conference a must is the ex-US pharma factor, and the whole reason for pharma’s need for global presence and expertise in market access, patient centricity, and healthcare professional (HCP) approaches.
The actual running of a pharma company or division has a universal approach. Executives presenting at the conference shared similar views on the needs for pharma achievement in the near-term. These include agile planning—the need to move those decisions from the traditional 18 months to 90 days; a simplified but more robust engagement model; and the agility to pivot from ways and strategies that don’t work anymore, and moving resources to those that do.
Highlights from the sessions: digital therapeutics, virtual reality, digital twins; integrating the patient voice has changed 100% of clinical trials and 45% of protocols at one pharma; a small pilot using AI to detect potential lung cancer in any imaging/chest x-rays performed to treat that cancer earlier and more efficiently; using data to predict a pain crisis common in sickle cell patients at higher risk for organ failure; and many insights on real-world evidence (RWE).
Again, the chance to learn from initiatives across Europe, some that transcend geography, and others that create opportunities out of local regulations, is for these attendees a true sharing event.
Another first in-person event that took place in October was our own second-annual Pharmaceutical Executive APEX Awards. After going virtual our first year, the second event was tastefully and beautifully executed in Gotham Hall, NYC by our MJH Life Sciences Live Events team.
Lisa Henderson is Pharm Exec’s Group Editorial Director. She can be reached at
Articles in this issue
almost 3 years ago
Labs and Computing Power: The Missing Link for a Revolution by 2030almost 3 years ago
A Culture of Quality: The Catalyst to Accelerate Innovationalmost 3 years ago
A Mission of the Heartalmost 3 years ago
The New Reality for Industry Dealmaking May be Setting Inalmost 3 years ago
Is ESG a ‘Protection Racket’ or Long-Term Value Contributor?almost 3 years ago
Digital Biomarkers Could Reshape CNS Diagnosis, Treatmentalmost 3 years ago
Long-Sought Reforms To EU Drug Rules Hit A Snag—What Now?almost 3 years ago
Pharmaceutical Executive, November 2022 Issue (PDF)about 3 years ago
FDA Keeps Its User Fees, but Fails to Gain Important ReformsNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.